Tag: diabetes

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?
Money

A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?

In pharma, you can take a larger slice of the healthcare pie than your peers, but you are still constrained by the size of the pie. No matter how good your cancer or diabetes drug is, healthcare systems will still have to keep paying for heart disease and rheumatoid arthritis treatments too.That, in a nutshell, is why the divergence of obesity-diabetes companies from the rest of the industry in recent years can’t go on forever. In 2023, Eli Lilly and Novo Nordisk have risen more than 50% each, to become the two largest pharma companies by market capitalization, with their combined value now hovering around $1 trillion. By comparison, the rest of the industry badly underperformed the market, with the NYSE Arca Pharmaceutical Index rising a measly 4% compared with 24% for the S&P 500.  ...
FDA issues warning about fake Ozempic
Health

FDA issues warning about fake Ozempic

FDA issues warning about fake Ozempic - CBS News Watch CBS News The Food and Drug Administration reports that it has seized thousands of units of counterfeit Ozempic, the popular diabetes medication that is also used for weight loss. Be the first to know Get browser notifications for breaking news, live events, and exclusive reporting. Not Now Turn On
Diabetic? Fold your hands in prayer sign and check for these symptoms​
Entertainment

Diabetic? Fold your hands in prayer sign and check for these symptoms​

Comments ()Sort: NewestUpVotedOldestDiscussedDown VotedclosecommentsCount: 3000XRefrain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks, name calling or inciting hatred against any community. Help us delete comments that do not follow these guidelines by marking them offensive. Let's work together to keep the conversation civil.Be the first one to review.We have sent you a verification email. To verify, just follow the link in the message
Roche Strikes Deal to Buy Drug Developer Carmot Therapeutics for $2.7 Bln
World

Roche Strikes Deal to Buy Drug Developer Carmot Therapeutics for $2.7 Bln

Roche aims to buy Carmot Therapeutics, a California-based pharmaceutical firm developing drugs to treat obesity and diabetes.The Swiss pharmaceutical company said it has entered an agreement to acquire the private company for $2.7 billion with additional payments of up to $400 million based on drug-development milestones.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Wegovy-Maker Novo Nordisk to Spend More Than $2 Billion Boosting Production in France
World

Wegovy-Maker Novo Nordisk to Spend More Than $2 Billion Boosting Production in France

Pharmaceutical giant Novo Nordisk said it will invest more than 16 billion Danish kroner ($2.34 billion) in its French production site as it seeks to meet rising demand for its blockbuster obesity and diabetes treatments.The Danish company, which makes the Wegovy obesity drug and diabetes drug Ozempic, said Thursday that the expansion of its facility in Chartres, southwest of Paris, will more than double the size of the site and is expected to create more than 500 new jobs. Construction, which has already started and will employ up to 2,000 external workers, is set to complete between 2026 and 2028, it said.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Research finds women who sleep less are at higher risk for diabetes
Health

Research finds women who sleep less are at higher risk for diabetes

Research finds women who sleep less are at higher risk for diabetes Research finds women who sleep less are at higher risk for diabetes 00:50 BOSTON - Getting just a little less sleep a night could increase the risk of diabetes in women.Throughout their lives, women often struggle to get a good night's rest, from discomfort during pregnancy, caring for young children who wake in the middle of the night, or the insomnia associated with menopa...
Novo Nordisk’s Wegovy Shows Heart Benefits Beyond Weight Loss, New Data Suggests
World

Novo Nordisk’s Wegovy Shows Heart Benefits Beyond Weight Loss, New Data Suggests

The effectiveness of Novo Nordisk’s blockbuster obesity treatment Wegovy in reducing heart attacks and strokes could be due to more than weight loss alone, according to new clinical trial data.The surging popularity of the drug has seen the Danish pharmaceutical giant scramble to boost production as it struggles to meet demand. It has been forced to limit supply of lower-strength doses of Wegovy in the U.S. as it seeks to safeguard supplies for current patients, and has outlined plans to invest more than $6 billion to boost production capacity.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Novo Nordisk Invests Over $6 Bln to Boost Production Capacity
World

Novo Nordisk Invests Over $6 Bln to Boost Production Capacity

Novo Nordisk will invest over 42 billion Danish kroner ($6.01 billion) to boost manufacturing capacity in Kalundborg, Denmark.Most of the new capacity will be dedicated to manufacturing active pharmaceutical ingredients, including for its blockbuster GLP-1 products for treating diabetes and obesity, which will increase the company’s ability to meet future market demands.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.
World

Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.

Updated Nov. 8, 2023 1:01 pm ETU.S. drug regulators have approved expanding the use of Eli Lilly’s diabetes drug Mounjaro to include the treatment of obesity.The Food and Drug Administration’s decision Wednesday furthers the rapid rise of Mounjaro—and similar-acting therapies Ozempic and Wegovy from Novo Nordisk—that have in a matter of months reshaped the treatment of obesity and doctors’ understanding of its roots.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8